Skip to main content

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA

Publication: J Thorac Oncol (2015) • Vol 10 • Page 1726-35PMID: 26473645View on PubMed

Purpose

The purpose of this paper was to determine if immunohistochemical staining of Programmed Cell Death Protein-1 (PD-1) and its ligands (Programmed Cell Death Ligand-1, PD-L1; Programmed Cell Death Ligand-2, PD-L2) in non-small cell lung cancer (NSCLC) patients with a KRAS mutation are affected by patient age, gender, or race; smoking history; tumor sampling method (core needle biopsy, CNB; transbronchial biopsy; fine needle aspiration, FNA); and the storage duration of formalin-fixed, paraffin-embedded (FFPE) blocks.

Conclusion

The percentage of KRAS-mutant tumors from NSCLC patient that were positive for PD-L1 expression, but not PD-L2 expression, differed significantly based on smoking status (44% current smokers, 20% of former smokers, 13% of never smokers; p=0.03). PD-L1 staining intensity also varied based on the intensity of smoking history of the patient, with stronger staining (2+ or 3+) observed more frequently in patients that had a higher ratio of cigarette packs/year. PD-L1 expression faded with FFPE block storage duration. When specimens were analyzed within 3 years of collection, there was a higher percentage of PD-L1 positive cases than when FFPE block storage was > 3 years (stored 1-3 y: 39%, stored 4-6 y: 15%, stored >6 y: 15%; p=0.016); However, PD-L2 expression was not affected by FFPE block storage. PD-L1, and PD-L2 immunostaining were not significantly influenced by patient age, gender, or race; the method of tumor sampling; or the type of KRAS mutation (transversion versus transition). The number of PD-1-positive tumor infiltrating lymphocytes (TILs) were not associated with the intensity of PD-L1 or PD-L2 staining, the smoking status of the patient.

Studies (1)

Purpose

The purpose of this paper was to determine if immunohistochemical staining of Programmed Cell Death Protein-1 (PD-1) and its ligands (Programmed Cell Death Ligand-1, PD-L1; Programmed Cell Death Ligand-2, PD-L2) in non-small cell lung cancer (NSCLC) patients with a KRAS mutation are affected by patient age, gender, or race; smoking history; tumor sampling method (core needle biopsy, CNB; transbronchial biopsy; fine needle aspiration, FNA); and the storage duration of formalin-fixed, paraffin-embedded (FFPE) blocks.  In total, 514 patients diagnosed with KRAS-mutant NSCLC that had previously undergone systematic genotyping were asked to complete a questionnaire that classified participants as a current smoker, a former smoker (ceased smoking 1 year prior), or a never smoker (smoked <100 cigarettes in their lifetime) and quantified the intensity of smoking by calculating “pack-years” [(mean number of cigarettes smoked per day/20) × years smoking].  Protein expression of PD-1, PD-L1, and PD-L2 were assayed by immunohistochemistry in tumor samples (85 surgical resections, 18 core needle or transbronchial biopsies, 11 FNA) collected from 114 KRAS-mutant patients (84 current/former smokers, 30 never smokers) using 4 µm-thick FFPE sections that underwent antigen retrieval by incubation in a steamer for 30 min in either citrate buffer, pH 6 (PD-1, PD-L2) or EDTA buffer, pH 8 (PD-L1) before incubation with a primary antibody, an horse radish peroxidase-conjugated secondary antibody, and diaminobenzidine labeling with a hematoxylin counterstain. Details regarding cold ischemia time; fixation and tissue processing conditions, duration, and temperatures; and FFPE block storage conditions were not provided. Staining was defined as positive for PD-L1 if ≥5% tumor cells displayed membrane staining, for PD-L2 if ≥10% of tumor cells were stained; staining intensity was also scored (0=negative, 1+ = weak, 2+ = moderate, 3+ = intense).  PD-1 staining was quantified as the number of stained tumor infiltrating lymphocytes (TILs) in 5 representative areas at a magnification of 20×.  Evaluation of all immunostaining was performed by a pathologist that was blinded to the associated clinical data. Of the 114 tumors that underwent IHC, 82% of patients had the biopsy at the time of diagnosis and had not received prior treatment.

Summary of Findings

KRAS-mutant tumors from NSCLC patients that identified as smokers displayed a significantly higher incidence of positive PD-L1 expression than tumors from nonsmokers (44% current smokers, 20% of former smokers, 13% of never smokers; p=0.03) and a greater incidence of high intensity PD-L1 immunostaining than tumors from nonsmokers (3+; p=0.03). However, the median percentage of PD-L1-positive tumor cells did not differ between smokers (current and former) and never smokers (70 versus 55%).  PD-L1 staining intensity was also influenced by the smoking history of the patient, as patients with a PD-L1 staining intensity of 2+ and 3+ had a significantly higher number of pack-years (34 cigarette packs/year) than patients with weaker staining (0-1+: 20 cigarette packs/year) (p=0.015).  The percentage of patients with a PD-L1 positive/negative status did not differ based on patient age, race, histology, type of KRAS mutation (transversion or a transition), and method of tumor sampling.  When specimens were analyzed within 3 years of collection, there was a higher percentage of PD-L1 positive cases than when FFPE block storage was for longer than 3 years (stored 1-3 y: 39%, stored 4-6 y: 15%, stored >6 y: 15%; p=0.016).

The percentage of patients with a PD-L2 positive/negative status did not differ based on patient age, gender, race; histology; type of KRAS mutation (transversion or a transition); tumor sampling method; smoking status of the patient; or storage duration of the FFPE block. There were no associations between the status or staining intensity of PD-L2 and PD-L1.  Nor was the number of PD-1-positive TILs associated with the intensity of PD-L1 or PD-L2 staining or the smoking status of the patient.

  • Biospecimens

    TissueLung
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    ProteinImmunohistochemistry
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Adenocarcinoma
    Adenosquamous
    Current smoker
    Former smoker (>1 y)
    Intensity of smoking history (3-115 pack years)
    KRAS transition
    KRAS transversion
    Large cell lung cancer
    NSCLC Not Otherwise Specified (NOS)
    Never Smoker (<100 cigarettes/life-time)
    Squamous
    PreaquisitionPatient age
    20-84 y
    PreaquisitionPatient gender
    Female
    Male
    PreaquisitionPatient race
    African American
    Asian
    Caucasian
    Hispanic
    Biospecimen AcquisitionMethod of tissue acquisition
    Core needle biopsy
    Fine needle aspiration
    Surgical resection
    Transbronchial biopsy
    StorageStorage duration
    1-3 y
    4-6 y
    >6 y
    Immunohistochemistry SpecificTargeted peptide/protein
    PD-1
    PD-L1
    PD-L2